Yan Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yan Zhang has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Jinghan Yang
Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China; Institute of Anesthesia and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China; Key Laboratory of Anesthesiology and Resuscitation (Huazhong University of Science and Technology), Ministry of Education, China
3 shared publicationsBo Shuai
Department of Integrated Traditional Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
2 shared publicationsHui Ding
Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China
2 shared publicationsJia Wang
2 shared publicationsLi Tang
Institute of Anesthesia and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China; Department of Pain, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
2 shared publications- Shanglong Yao
Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2 shared publications
Latest Publications
- Open Access
- 12 September 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1) , 1177
Current state of research and future developments of artificial intelligence in pain diagnosis and treatment
Chronic pain represents a significant global health challenge, with traditional diagnostic and therapeutic approaches facing limitations in objective asses
- 12 September 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1) , 1177
Open AccessCurrent state of research and future developments of artificial intelligence in pain diagnosis and treatment
Chronic pain represents a significant global health challenge, with traditional diagnostic and therapeutic approaches facing limitations in objective asses
- Open Access
- 24 July 2025
- Published by AIP Publishing in APL Bioengineering
- Vol. 9 (3) , 036108
Quercetin targets the Ccl4–Ccr5 axis to relieve neuropathic pain after spinal cord injury
Spinal cord injury (SCI) severely disrupts the central nervous system, with neuropathic pain (NP) emerging as a prevalent and challenging complication, affecting approximately two-thirds of affected individuals. This study aims to explore the immune landscape and potential drug therapeutic targets associated with NP post-SCI using single-cell and bulk RNA sequencing. We identified 1050 differentially expressed genes enriched in cytokine interactions and inflammatory pathways, including key pain-related genes like Itgb2, Ccr5, Fcrg3, and Adora3, through weighted gene co-expression network analysis and immune infiltration analysis. Cell communication analysis revealed the pivotal role of the Ccl4–Ccr5 signaling axis in the interaction between macrophages and natural killer cell, thereby intensifying neuroinflammatory responses and aberrant nociceptive signaling, which may contribute to apoptosis after SCI. Molecular docking and molecular dynamics simulations showed that quercetin had stable binding with Ccr5 and identified potential amino acid binding sites TYR-108 and PHE-109. In vivo experiments demonstrated that Ccr5 inhibitors and quercetin effectively improved the Basso mouse scale and mechanical withdrawal threshold score, concurrently attenuating spinal tissue apoptosis. Therefore, we propose that quercetin and Ccr5 inhibitors could potentially treat NP post-SCI by inhibiting the Ccl4–Ccr5 pathway and reducing apoptosis, providing new treatment avenues.
- 24 July 2025
- Published by AIP Publishing in APL Bioengineering
- Vol. 9 (3) , 036108
Open AccessQuercetin targets the Ccl4–Ccr5 axis to relieve neuropathic pain after spinal cord injury
Spinal cord injury (SCI) severely disrupts the central nervous system, with neuropathic pain (NP) emerging as a prevalent and challenging complication, affecting approximately two-thirds of affected individuals. This study aims to explore the immune landscape and potential drug therapeutic targets associated with NP post-SCI using single-cell and bulk RNA sequencing. We identified 1050 differentially expressed genes enriched in cytokine interactions and inflammatory pathways, including key pain-related genes like Itgb2, Ccr5, Fcrg3, and Adora3, through weighted gene co-expression network analysis and immune infiltration analysis. Cell communication analysis revealed the pivotal role of the Ccl4–Ccr5 signaling axis in the interaction between macrophages and natural killer cell, thereby intensifying neuroinflammatory responses and aberrant nociceptive signaling, which may contribute to apoptosis after SCI. Molecular docking and molecular dynamics simulations showed that quercetin had stable binding with Ccr5 and identified potential amino acid binding sites TYR-108 and PHE-109. In vivo experiments demonstrated that Ccr5 inhibitors and quercetin effectively improved the Basso mouse scale and mechanical withdrawal threshold score, concurrently attenuating spinal tissue apoptosis. Therefore, we propose that quercetin and Ccr5 inhibitors could potentially treat NP post-SCI by inhibiting the Ccl4–Ccr5 pathway and reducing apoptosis, providing new treatment avenues.
- Open Access
- 1 March 2025
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 24 (1) , 1-12
Associations of triglyceride glucose-body mass index and the combination of sedentary behavior and physical activity with risks of all-cause mortality and myocardial infarction: a cohort study from the UK biobank
Triglyceride glucose-body mass (TyG-BMI) index, sedentary behavior (SB) and physical activity (PA) are independently associated with all-cause mortality and myocardial infarction (MI). However, it remains unclear whether TyG-BMI index and the combination of SB and PA exhibit joint effects on all-cause mortality and MI. Among 502 356 participants from the UK Biobank, 297 761 eligible participants were selected. The Cox proportional hazards model and the restricted cubic spline regression model were used to assess the associations of TyG-BMI with all-cause mortality and MI. To conduct stratified analysis, participants were classified into four groups by SB (<6 h/d and ≥ 6 h/d) and moderate to vigorous physical activity (MVPA) (<150 min/wk and ≥ 150 min/wk). Additionally, the multiplicative interaction was assessed between TyG-BMI and SB & MVPA. Furthermore, to estimate their joint associations, participants were conjointly classified into twelve new groups by TyG-BMI (tertiles) and SB & MVPA (four groups). During a median follow-up of 13.8 and 13.6 years, 21 335 deaths and 9 116 MI were observed, respectively. The dose-response relationship of TyG-BMI with all-cause mortality was U-shaped with a cut-off point at 225.09, whereas the relationship with MI was positive nonlinear with a cut-off point at 266.87. A synergistic effect on all-cause mortality was observed between TyG-BMI tertile 1 and ≥ 6 h/d SB & <150 min/wk MVPA (P for interaction < 0.001). When MVPA ≥ 150 min/wk combined with SB either <6 h/d or not, TyG-BMI tertile 2 showed no significant association with all-cause mortality risk, with HRs(95%CIs) of 0.98 (0.93–1.03) for <6 h/d SB and 1.00 (0.94–1.07) for ≥ 6 h/d SB. When one of the two healthy behaviors was present (i.e., either <6 h/d SB with <150 min/wk MVPA, or ≥ 150 min/wk MVPA with ≥ 6 h/d SB), its combination with TyG-BMI tertile 1 showed no significant association with MI risk, with HRs(95%CIs) of 1.07(0.95–1.20) and 1.09(0.94–1.25), respectively. TyG-BMI index and the combination of SB and PA were independently and jointly associated with risks of all-cause mortality and MI. Our findings highlight the importance of improving insulin resistance to reduce all-cause mortality risk, particularly in individuals with long-term SB and insufficient PA, who are more susceptible to the adverse effects of TyG-BMI index. In long-term sedentary individuals, meeting PA guidelines (≥ 150 min/wk of MVPA) effectively mitigated risks of all-cause mortality and MI associated with TyG-BMI index.
- 1 March 2025
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 24 (1) , 1-12
Open AccessAssociations of triglyceride glucose-body mass index and the combination of sedentary behavior and physical activity with risks of all-cause mortality and myocardial infarction: a cohort study from the UK biobank
Triglyceride glucose-body mass (TyG-BMI) index, sedentary behavior (SB) and physical activity (PA) are independently associated with all-cause mortality and myocardial infarction (MI). However, it remains unclear whether TyG-BMI index and the combination of SB and PA exhibit joint effects on all-cause mortality and MI. Among 502 356 participants from the UK Biobank, 297 761 eligible participants were selected. The Cox proportional hazards model and the restricted cubic spline regression model were used to assess the associations of TyG-BMI with all-cause mortality and MI. To conduct stratified analysis, participants were classified into four groups by SB (<6 h/d and ≥ 6 h/d) and moderate to vigorous physical activity (MVPA) (<150 min/wk and ≥ 150 min/wk). Additionally, the multiplicative interaction was assessed between TyG-BMI and SB & MVPA. Furthermore, to estimate their joint associations, participants were conjointly classified into twelve new groups by TyG-BMI (tertiles) and SB & MVPA (four groups). During a median follow-up of 13.8 and 13.6 years, 21 335 deaths and 9 116 MI were observed, respectively. The dose-response relationship of TyG-BMI with all-cause mortality was U-shaped with a cut-off point at 225.09, whereas the relationship with MI was positive nonlinear with a cut-off point at 266.87. A synergistic effect on all-cause mortality was observed between TyG-BMI tertile 1 and ≥ 6 h/d SB & <150 min/wk MVPA (P for interaction < 0.001). When MVPA ≥ 150 min/wk combined with SB either <6 h/d or not, TyG-BMI tertile 2 showed no significant association with all-cause mortality risk, with HRs(95%CIs) of 0.98 (0.93–1.03) for <6 h/d SB and 1.00 (0.94–1.07) for ≥ 6 h/d SB. When one of the two healthy behaviors was present (i.e., either <6 h/d SB with <150 min/wk MVPA, or ≥ 150 min/wk MVPA with ≥ 6 h/d SB), its combination with TyG-BMI tertile 1 showed no significant association with MI risk, with HRs(95%CIs) of 1.07(0.95–1.20) and 1.09(0.94–1.25), respectively. TyG-BMI index and the combination of SB and PA were independently and jointly associated with risks of all-cause mortality and MI. Our findings highlight the importance of improving insulin resistance to reduce all-cause mortality risk, particularly in individuals with long-term SB and insufficient PA, who are more susceptible to the adverse effects of TyG-BMI index. In long-term sedentary individuals, meeting PA guidelines (≥ 150 min/wk of MVPA) effectively mitigated risks of all-cause mortality and MI associated with TyG-BMI index.
- Open Access
- 29 May 2024
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 659, 124276
Diclofenac sodium nanomedicine results in pain-relief and differential expression of the RNA transcriptome in the spinal cord of SNI rats
- 29 May 2024
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 659, 124276
Open AccessDiclofenac sodium nanomedicine results in pain-relief and differential expression of the RNA transcriptome in the spinal cord of SNI rats
- Open Access
- 15 July 2023
- Published by Springer Nature in The Journal of Headache and Pain
- Vol. 24 (1) , 1-11
Notch signaling pathway: a new target for neuropathic pain therapy
The Notch gene, a highly evolutionarily conserved gene, was discovered approximately 110 years ago and has been found to play a crucial role in the development of multicellular organisms. Notch receptors and their ligands are single-pass transmembrane proteins that typically require cellular interactions and proteolytic processing to facilitate signal transduction. Recently, mounting evidence has shown that aberrant activation of the Notch is correlated with neuropathic pain. The activation of the Notch signaling pathway can cause the activation of neuroglia and the release of pro-inflammatory factors, a key mechanism in the development of neuropathic pain. Moreover, the Notch signaling pathway may contribute to the persistence of neuropathic pain by enhancing synaptic transmission and calcium inward flow. This paper reviews the structure and activation of the Notch signaling pathway, as well as its potential mechanisms of action, to provide novel insights for future treatments of neuropathic pain.
- 15 July 2023
- Published by Springer Nature in The Journal of Headache and Pain
- Vol. 24 (1) , 1-11
Open AccessNotch signaling pathway: a new target for neuropathic pain therapy
The Notch gene, a highly evolutionarily conserved gene, was discovered approximately 110 years ago and has been found to play a crucial role in the development of multicellular organisms. Notch receptors and their ligands are single-pass transmembrane proteins that typically require cellular interactions and proteolytic processing to facilitate signal transduction. Recently, mounting evidence has shown that aberrant activation of the Notch is correlated with neuropathic pain. The activation of the Notch signaling pathway can cause the activation of neuroglia and the release of pro-inflammatory factors, a key mechanism in the development of neuropathic pain. Moreover, the Notch signaling pathway may contribute to the persistence of neuropathic pain by enhancing synaptic transmission and calcium inward flow. This paper reviews the structure and activation of the Notch signaling pathway, as well as its potential mechanisms of action, to provide novel insights for future treatments of neuropathic pain.
- Open Access
- 4 January 2023
- Published by Frontiers Media SA in Frontiers in Molecular Neuroscience
- Vol. 15, 1081288
Mechanism and effects of STING–IFN-I pathway on nociception: A narrative review
Since the discovery of STING in 2008, numerous studies have investigated its functions in immunity, inflammation, and cancer. STING activates downstream molecules including IFN-I, NLRP3, and NF-κB. The STING–IFN-I pathway plays a vital role in nociception. After receiving the upstream signal, STING is activated and induces the expression of IFN-I, and after paracrine and autocrine signaling, IFN-I binds to IFN receptors. Subsequently, the activity of ion channels is inhibited by TYK2, which induces an acute antinociceptive effect. JAK activates PIK3 and MAPK–MNK–eIF4E pathways, which sensitize nociceptors in the peripheral nervous system. In the mid-late stage, the STING–IFN-I pathway activates STAT, increases pro-inflammatory and anti-inflammatory cytokines, inhibits ER-phagy, and promotes microglial M1-polarization in the central nervous system, leading to central sensitization. Thus, the STING–IFN-I pathway may exert complex effects on nociception at various stages, and these effects require further comprehensive elucidation. Therefore, in this review, we systematically summarized the mechanisms of the STING–IFN-I pathway and discussed its function in nociception.
- 4 January 2023
- Published by Frontiers Media SA in Frontiers in Molecular Neuroscience
- Vol. 15, 1081288
Open AccessMechanism and effects of STING–IFN-I pathway on nociception: A narrative review
Since the discovery of STING in 2008, numerous studies have investigated its functions in immunity, inflammation, and cancer. STING activates downstream molecules including IFN-I, NLRP3, and NF-κB. The STING–IFN-I pathway plays a vital role in nociception. After receiving the upstream signal, STING is activated and induces the expression of IFN-I, and after paracrine and autocrine signaling, IFN-I binds to IFN receptors. Subsequently, the activity of ion channels is inhibited by TYK2, which induces an acute antinociceptive effect. JAK activates PIK3 and MAPK–MNK–eIF4E pathways, which sensitize nociceptors in the peripheral nervous system. In the mid-late stage, the STING–IFN-I pathway activates STAT, increases pro-inflammatory and anti-inflammatory cytokines, inhibits ER-phagy, and promotes microglial M1-polarization in the central nervous system, leading to central sensitization. Thus, the STING–IFN-I pathway may exert complex effects on nociception at various stages, and these effects require further comprehensive elucidation. Therefore, in this review, we systematically summarized the mechanisms of the STING–IFN-I pathway and discussed its function in nociception.